BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -693 Thousand EUR | 87.18% |
| 2022 | -5.4 Million EUR | 75.32% |
| 2021 | -21.9 Million EUR | -287.94% |
| 2020 | 11.65 Million EUR | -11.83% |
| 2019 | 13.21 Million EUR | 485.9% |
| 2018 | 2.25 Million EUR | 107.71% |
| 2017 | -29.25 Million EUR | -2147.46% |
| 2016 | 1.42 Million EUR | -89.16% |
| 2015 | 13.17 Million EUR | 3912.61% |
| 2014 | 328.39 Thousand EUR | 105.73% |
| 2013 | -5.73 Million EUR | -126.18% |
| 2012 | -2.53 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 27.32 Million EUR | 700.11% |
| 2024 Q1 | -4.55 Million EUR | -557.14% |
| 2024 Q3 | -12.96 Million EUR | -147.44% |
| 2023 Q3 | -5.32 Million EUR | -127.28% |
| 2023 Q4 | -693 Thousand EUR | 86.98% |
| 2023 FY | -693 Thousand EUR | 87.18% |
| 2023 Q1 | -10.76 Million EUR | -99.08% |
| 2023 Q2 | 19.5 Million EUR | 281.22% |
| 2022 Q3 | -13.3 Million EUR | -230.16% |
| 2022 Q2 | 10.22 Million EUR | 145.09% |
| 2022 Q1 | -22.67 Million EUR | -3.54% |
| 2022 FY | -5.4 Million EUR | 75.32% |
| 2022 Q4 | -5.4 Million EUR | 59.38% |
| 2021 FY | -21.9 Million EUR | -287.94% |
| 2021 Q2 | 15 Million EUR | 193.14% |
| 2021 Q3 | -7.24 Million EUR | -148.3% |
| 2021 Q4 | -21.9 Million EUR | -202.14% |
| 2021 Q1 | -16.11 Million EUR | -238.26% |
| 2020 Q2 | 27.39 Million EUR | 306.74% |
| 2020 Q3 | -18.78 Million EUR | -168.59% |
| 2020 Q4 | 11.65 Million EUR | 162.03% |
| 2020 FY | 11.65 Million EUR | -11.83% |
| 2020 Q1 | -13.24 Million EUR | -200.23% |
| 2019 Q3 | -15.4 Million EUR | -276.2% |
| 2019 FY | 13.21 Million EUR | 485.9% |
| 2019 Q4 | 13.21 Million EUR | 185.82% |
| 2019 Q2 | 8.74 Million EUR | 136.69% |
| 2019 Q1 | -23.82 Million EUR | -1155.98% |
| 2018 Q3 | -25.99 Million EUR | -1030.28% |
| 2018 Q4 | 2.25 Million EUR | 108.68% |
| 2018 FY | 2.25 Million EUR | 107.71% |
| 2018 Q1 | -39.46 Million EUR | -34.87% |
| 2018 Q2 | 2.79 Million EUR | 107.08% |
| 2017 FY | -29.25 Million EUR | -2147.46% |
| 2017 Q1 | -4.47 Million EUR | -412.8% |
| 2017 Q2 | -1.82 Million EUR | 59.17% |
| 2017 Q3 | -8.14 Million EUR | -346.03% |
| 2017 Q4 | -29.25 Million EUR | -259.45% |
| 2016 FY | 1.42 Million EUR | -89.16% |
| 2016 Q4 | 1.42 Million EUR | 107.59% |
| 2016 Q2 | 1.01 Million EUR | 140.88% |
| 2016 Q1 | -2.49 Million EUR | -118.94% |
| 2016 Q3 | -18.83 Million EUR | -1946.75% |
| 2015 Q4 | 13.17 Million EUR | 0.0% |
| 2015 Q1 | 4.45 Million EUR | 0.0% |
| 2015 FY | 13.17 Million EUR | 3912.61% |
| 2014 FY | 328.39 Thousand EUR | 105.73% |
| 2013 FY | -5.73 Million EUR | -126.18% |
| 2012 FY | -2.53 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 99.994% |
| CureVac N.V. | -360.92 Million EUR | 99.808% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 100.121% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 100.121% |
| Formycon AG | 2.45 Million EUR | 128.274% |
| Heidelberg Pharma AG | -37.6 Million EUR | 98.157% |
| Medigene AG | -5.72 Million EUR | 87.893% |